#Canada #Ottawa #Sonorous Neurovascular #B-SILENT Study #BosSTENT

Sonorous Neurovascular Expands Global Impact with Canadian Enrollment in B-SILENT Study

Sonorous Neurovascular, a leading medical device company focused on pioneering treatments for cerebral venous conditions and neurovascular issues, has recently hit a significant clinical milestone. The company successfully enrolled its first patient in Canada for the international B-SILENT study, which took place at The Ottawa Hospital under the guidance of Dr. Robert Fahed. This accomplishment not only signifies a promising step for Sonorous Neurovascular but also enhances its global momentum in the treatment of pulsatile tinnitus.

What is the B-SILENT Study?

The B-SILENT study aims to investigate the effectiveness of the BosSTENT™, a self-expanding cerebral venous stent developed by Sonorous, intended to address the debilitating condition of pulsatile tinnitus—an ailment often linked to symptomatic cerebral venous sinus stenosis. The trial is designed to provide crucial safety and performance data, which are essential for future regulatory submissions, including a CE Mark that would enable the stent to be distributed more widely in Europe.

Principal Investigator Dr. Fahed expressed excitement about this first enrollment, noting, “Pulsatile tinnitus can be a debilitating and often under-recognized condition. Studies like B-SILENT are vital for providing new tools physicians can use to help their patients.” His sentiments reflect the general anticipation surrounding the trail’s potential contributions to better medical options for those suffering from limited treatment choices.

Building International Momentum

The first Canadian enrollment is a landmark in the B-SILENT study timeline. With ongoing patient recruitment in France and the recent activation of multiple clinical sites in Canada, Sonorous Neurovascular is witnessing a growing interest in this innovative research. CEO Joel Harris highlighted that the enrollment achievements underscore the promising trajectory of the B-SILENT study. “With our first Canadian enrollment complete and sites actively engaging patients across France as well, B-SILENT is moving ahead exactly as we planned,” said Harris, emphasizing the collaborative efforts with Dr. Fahed and the clinical teams involved.

Regulatory Progress

Sonorous Neurovascular's advancements are not limited to the B-SILENT study. The company recently received a Breakthrough Device Designation from the FDA for BosSTENT™ and has been granted 510(k) clearance for its BosCATH™ neurovascular catheter. These achievements reflect the company’s commitment to innovating minimally invasive therapies that significantly improve the quality of life for patients afflicted by pulsatile tinnitus and various venous disorders.

The B-SILENT study is pivotal in moving towards a broader understanding of treatment options for ailments that affect quality of life. With its sights set on expanding its clinical investigations, Sonorous Neurovascular is determined to enhance patient outcomes through its highly specialized solutions.

Conclusion

As Sonorous Neurovascular continues to make strides in clinical research and collaboration, the medical community remains hopeful for improved interventions in treating challenging conditions like pulsatile tinnitus. The B-SILENT study not only serves as a beacon of innovation but also symbolizes the growing dedication to patient care in the realm of neurovascular health. For additional information about the B-SILENT study and Sonorous Neurovascular’s ongoing projects, visit www.sonorousnv.com.